Loading...
Header Logo
Keywords
Last Name
Institution

MOSES MAKOKHA KASEMBELI


    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zhang L, Wang Y, Dong Y, Chen Z, Eckols TK, Kasembeli MM, Tweardy DJ, Mitch WE. Pharmacokinetics (PK) and pharmacodynamics (PD) of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease. Am J Physiol Renal Physiol. 2020 Jun 01. PMID: 32475130.
      View in: PubMed
    2. Minus MB, Wang H, Munoz JO, Stevens AM, Mangubat-Medina AE, Krueger MJ, Liu W, Kasembeli MM, Cooper JC, Kolosov MI, Tweardy DJ, Redell MS, Ball ZT. Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors. Org Biomol Chem. 2020 May 06; 18(17):3288-3296. PMID: 32286579.
      View in: PubMed
    3. Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Pharmacol Rev. 2020 04; 72(2):486-526. PMID: 32198236.
      View in: PubMed
    4. Bharadwaj U, Eckols TK, Xu X, Kasembeli MM, Chen Y, Adachi M, Song Y, Mo Q, Lai SY, Tweardy DJ. Correction: Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2019 02 22; 10(16):1603. PMID: 30899429.
      View in: PubMed
    5. Kasembeli MM, Bharadwaj U, Robinson P, Tweardy DJ. Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment. Int J Mol Sci. 2018 Aug 05; 19(8). PMID: 30081609.
      View in: PubMed
    6. Bocchini CE, Nahmod K, Katsonis P, Kim S, Kasembeli MM, Freeman A, Lichtarge O, Makedonas G, Tweardy DJ. Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome. Blood. 2016 12 29; 128(26):3061-3072. PMID: 27799162.
      View in: PubMed
    7. Roh SH, Kasembeli MM, Galaz-Montoya JG, Chiu W, Tweardy DJ. Chaperonin TRiC/CCT Recognizes Fusion Oncoprotein AML1-ETO through Subunit-Specific Interactions. Biophys J. 2016 06 07; 110(11):2377-2385. PMID: 27276256.
      View in: PubMed
    8. Bharadwaj U, Eckols TK, Xu X, Kasembeli MM, Chen Y, Adachi M, Song Y, Mo Q, Lai SY, Tweardy DJ. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016 May 03; 7(18):26307-30. PMID: 27027445.
      View in: PubMed
    9. Li N, Feng L, Liu H, Wang J, Kasembeli M, Tran MK, Tweardy DJ, Lin SH, Chen J. PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Rep. 2016 Apr 26; 15(4):843-856. PMID: 27149849.
      View in: PubMed
    10. Robinson P, Kasembeli M, Bharadwaj U, Engineer N, Eckols KT, Tweardy DJ. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance. Biomed Res Int. 2016; 2016:1959270. PMID: 26981525.
      View in: PubMed
    11. Roh SH, Kasembeli M, Galaz-Montoya JG, Trnka M, Lau WC, Burlingame A, Chiu W, Tweardy DJ. Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO. J Biol Chem. 2016 Feb 26; 291(9):4732-41. PMID: 26706127.
      View in: PubMed
    12. Roh SH, Kasembeli M, Bakthavatsalam D, Chiu W, Tweardy DJ. Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis. Int J Mol Sci. 2015 Nov 06; 16(11):26706-20. PMID: 26561808.
      View in: PubMed
    13. Lewis KM, Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Fridley C, Siller R, Tweardy DJ. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lung Cancer. 2015 Nov; 90(2):182-90. PMID: 26410177.
      View in: PubMed
    14. Minus MB, Liu W, Vohidov F, Kasembeli MM, Long X, Krueger MJ, Stevens A, Kolosov MI, Tweardy DJ, Sison EA, Redell MS, Ball ZT. Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity. Angew Chem Int Ed Engl. 2015 Oct 26; 54(44):13085-9. PMID: 26480340.
      View in: PubMed
    15. Bocchini CE, Kasembeli MM, Roh SH, Tweardy DJ. Contribution of chaperones to STAT pathway signaling. JAKSTAT. 2014; 3(3):e970459. PMID: 26413421.
      View in: PubMed
    16. Bharadwaj U, Kasembeli MM, Eckols TK, Kolosov M, Lang P, Christensen K, Edwards DP, Tweardy DJ. Monoclonal Antibodies Specific for STAT3ß Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer. Cancers (Basel). 2014 Sep 29; 6(4):2012-34. PMID: 25268166.
      View in: PubMed
    17. Kasembeli M, Lau WC, Roh SH, Eckols TK, Frydman J, Chiu W, Tweardy DJ. Modulation of STAT3 folding and function by TRiC/CCT chaperonin. PLoS Biol. 2014 Apr; 12(4):e1001844. PMID: 24756126.
      View in: PubMed
    18. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One. 2009; 4(3):e4783. PMID: 19274102.
      View in: PubMed
    19. Kasembeli MM, Xu X, Tweardy DJ. SH2 domain binding to phosphopeptide ligands: potential for drug targeting. Front Biosci (Landmark Ed). 2009 Jan 01; 14:1010-22. PMID: 19273114.
      View in: PubMed
    20. Chaperonin TRiC/CCT modulates the folding and activity of leukemogenic fusion oncoprotein AML1-ETO. Journal of Biological Chemistry. 291:4732-4741.
    21. Contribution of the type II chaperonin, TRiC/CCT, to oncogenesis. International Journal of Molecular Sciences. 16:26706-26720.
    22. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lung Cancer.
    23. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance. BioMed Research International. 2016.
    24. Chaperonin TRiC/CCT Recognizes Fusion Oncoprotein AML1-ETO through Subunit-Specific Interactions. Biophysical Journal. 110:2377-2385.
    25. Monoclonal antibodies specific for Stat3β reveal its contribution to constitutive Stat3 phosphorylation in breast cancer. Cancers. 6:2012-2034.
    26. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 7:26307-26330.
    27. PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Reports. 15:843-856.
    28. Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity. Angewandte Chemie - International Edition. 54:13085-13089.
    KASEMBELI's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description